1、 教育经历
(1) 2016-09 至 2021-06, 南京大学, 基础医学, 博士
(2) 2012-09 至 2016-06, 中国药科大学, 药学, 学士
2、工作经历
2021-12 至 今, 中国药科大学, 生命科学与技术学院, 博士后（助理研究员）
1、抗病毒天然免疫
2、肿瘤表观遗传调控机制
1. 中国博士后科学基金项目, 抑制DNA甲基转移酶调控PAR4的抗胰腺癌作用研究，2022M723506, 2022-2024, 主持
2. 江苏省卓越博士后计划，2022-2024，主持
(1) Qi Gao, Ai Wei, Fang Chen, Xingren Chen, Wenwen Ding, Zhiquan Ding, Zhiwei Wu, Ronghui Du*, Wangsen Cao*. Enhancing PPARγ by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice. Pharmacological Research. 2020,160:105059.
(2) Qi Gao, Fang Chen; Lijun Zhang; Ai Wei; Yongxiang Wang; Zhiwei Wu*; Wangsen Cao*. Inhibition of DNA methyltransferase aberrations reinstates antioxidant aging suppressors and ameliorates renal aging. Aging Cell. 2022, 21(1): e13526.
(3) Fang Chen, Qi Gao, Ai Wei, Xingren Chen, Yujun Shi, Hongwei Wang*, Wangsen Cao*. Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis. Cell Death & Differentiation. 2020, 28(3): 1001-1012.
(4) Ai Wei, Qi Gao, Fang Chen, Xiaobo Zhu, Xingren Chen, Lijun Zhang, Xin Su, Jinghong Dai, Yi Shi*, Wangsen Cao*. Inhibition of DNA methylation de-represses peroxisome proliferator-activated receptor-γ and attenuates pulmonary fibrosis. British Journal of Pharmacology. 2022, 179(7): 1304-1318.
(5) Fang Chen, Qi Gao, Lijun Zhang, Yibing Ding, Hongwei Wang*, Wangsen Cao*. Inhibiting HDAC3 (Histone Deacetylase 3) Aberration and the Resultant Nrf2 (Nuclear Factor Erythroid-Derived 2-Related Factor-2) Repression Mitigates Pulmonary Fibrosis. Hypertension. 2021, 78(2): e15-e25.
